Clinical Trial Update: Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating Imexon in combination with dacarbazine (DTIC) for advanced malignant melanoma, focusing on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Dacarbazine (DTIC) (dacarbazine)
• Imexon (imexon)

Snippet

Sponsor: AmpliMed Corporation | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED